Emollient topical disinfectants

Abstract

This invention relates generally to an emollient topical composition of matter that contains molecular iodine with a reduced effective vapor pressure. In specific embodiments, the composition reduces the loss of molecular iodine to the atmosphere under storage conditions after application to mammalian tissue.

1 . A composition comprising an organic carrier molecule and molecular iodine, and the vapor pressure of molecular iodine in the composition being at least two magnitudes lower than the vapor pressure of molecular iodine in water. 
     
     
         2 . The composition of  claim 1 , wherein the organic carrier molecule is propylene glycol, glycerol or a combination thereof. 
     
     
         3 . The composition of  claim 1 , wherein the concentration of molecular iodine is between about 10 ppm and about 1000 ppm. 
     
     
         4 . The composition of  claim 1 , wherein the ratio of molecular iodine to all iodine species is at least about 70%. 
     
     
         5 . The composition of  claim 1 , wherein the ratio of molecular iodine to all iodine species is at least about 90%. 
     
     
         6 - 9 . (canceled) 
     
     
         10 . The composition of  claim 1 , wherein the composition further comprises one or more organic molecules. 
     
     
         11 . The composition of  claim 1 , wherein the organic molecule is selected from monomethyl ether, acetate, amyl alcohol, ethyl acetate, butyl acetate, 1-propanol and 2-propanol, dimethyl sulfoxide, iso-propanol, and ethanol. 
     
     
         12 . The composition of  claim 1 , wherein the composition is packaged in a single compartment container. 
     
     
         13 - 14 . (canceled) 
     
     
         15 . The composition of  claim 1 , wherein the composition is packaged in a package that contains an integrated applicator such that said composition impregnates said applicator wherein said applicator is designed to allow facile application of said emollient composition to mammalian tissues such as the interior surfaces of a human nose. 
     
     
         16 - 20 . (canceled) 
     
     
         21 . The composition of  claim 1 , further comprising a saturated fatty acid selected from the group including includes lactic acid, myristic acid, 1-monolaurin, dodeconic acid and caprylic acid. 
     
     
         22 . The composition of  claim 1  formulated for dermal application. 
     
     
         23 . The composition of  claim 22 , wherein the dermal application is epicutaneous. 
     
     
         24 . The composition of  claim 23 , wherein the dermal application is a cream, foam, gel, lotion or ointment dosage form. 
     
     
         25 . The composition of  claim 23 , wherein the dermal application is in the form of a hand sanitizer. 
     
     
         26 . The composition of  claim 1  formulated for nasal application. 
     
     
         27 . The composition of  claim 26 , wherein the nasal application is a spray dosage form. 
     
     
         28 . The composition of  claim 27 , wherein the spray dosage form is in the form of a metered dose inhaler. 
     
     
         29 . (canceled) 
     
     
         30 . A method for treating a bacterial infection comprising administering a therapeutically effective amount of the composition of  claim 1 . 
     
     
         31 . A method for treating or preventing a hospital acquired infection comprising administering an effective amount of the composition of  claim 1 . 
     
     
         32 . The method of  claim 31 , wherein the hospital acquired infection is  Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii  and Enterobacteriaceae including  E. coli, Klebsiella pneumoniae, Shigella  or  Yersinia.